Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00207116
First received: September 12, 2005
Last updated: October 26, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2006
  Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)